Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$99.04M$99.04M+26.2% vs Q3 2018 Net Income-$126.33M-$126.33MN/M vs Q3 2018 EPS Diluted-$1.70-$1.70N/M vs Q3 2018 Operating Income-$123,590,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$76,860,000N/M Margins · derivedOperating margin-124.8%−35.5 pt vs Q3 2018
Net margin-127.5%−30.2 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 7, 2019 · 38 d after period end